Payment overview · 2025
General Payments
$488.88
24 reported records · 9 companies
Healthcare provider profile · identity verified
Zia Khan, MD
Allopathic & Osteopathic Physicians|Internal Medicine · PEACHTREE CITY, GA · NPI 1427122092
Verified facts
What the public records show
CMS Open Payments records show Zia Khan, MD received $488.88 in general payments during 2025 across 24 reported records.
PFIZER INC. accounted for 32.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Rexulti.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 343 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1718 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $159.23 | 32.6% | 8 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $96.34 | 19.7% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $68.19 | 13.9% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $41.19 | 8.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $35.02 | 7.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $33.73 | 6.9% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $24.40 | 5.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.79 | 3.4% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $13.99 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $488.88 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $101.84 | 6 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $96.34 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $70.54 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $68.19 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $68.19 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $35.02 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $35.02 | 2 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $32.49 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $31.30 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $24.40 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $20.66 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $17.89 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $16.79 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.84 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 1718 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 81 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
89 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
65 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
343 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
75 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
75 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
81 | 28 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1718 | 106 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 2829 | 236 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 2754 | 154 |
| Gabapentin | Gabapentin | 2338 | 154 |
| Atorvastatin Calcium | Atorvastatin Calcium | 2009 | 209 |
| Memantine Hcl | Memantine Hcl | 1737 | 82 |
| Eliquis | Apixaban | 1718 | 106 |
| Famotidine | Famotidine | 1693 | 82 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1619 | 113 |
| Lisinopril | Lisinopril | 1594 | 119 |
| Metoprolol Tartrate | Metoprolol Tartrate | 1532 | 87 |
| Donepezil Hcl | Donepezil Hcl | 1406 | 67 |
| Trazodone Hcl | Trazodone Hcl | 1321 | 76 |
| Potassium Chloride | Potassium Chloride | 1319 | 95 |
| Quetiapine Fumarate | Quetiapine Fumarate | 1275 | 66 |
| Omeprazole | Omeprazole | 1236 | 110 |
| Sertraline Hcl | Sertraline Hcl | 1199 | 59 |
| Clopidogrel | Clopidogrel Bisulfate | 1130 | 66 |
| Tamsulosin Hcl | Tamsulosin Hcl | 1120 | 85 |
| Duloxetine Hcl | Duloxetine Hcl | 1086 | 44 |
| Escitalopram Oxalate | Escitalopram Oxalate | 1082 | 88 |
| Furosemide | Furosemide | 1064 | 101 |
| Buspirone Hcl | Buspirone Hcl | 1044 | 41 |
| Mirtazapine | Mirtazapine | 1005 | 65 |
| Metoprolol Succinate | Metoprolol Succinate | 920 | 82 |
| Losartan Potassium | Losartan Potassium | 850 | 80 |
| Baclofen | Baclofen | 846 | 37 |
| Metformin Hcl | Metformin Hcl | 831 | 76 |
| Divalproex Sodium | Divalproex Sodium | 785 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 754 | 95 |
| Hydralazine Hcl | Hydralazine Hcl | 751 | 40 |
| Carvedilol | Carvedilol | 701 | 54 |
| Levetiracetam | Levetiracetam | 627 | 44 |
| Fluoxetine Hcl | Fluoxetine Hcl | 584 | 38 |
| Sucralfate | Sucralfate | 542 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 522 | 33 |
| Bupropion Xl | Bupropion Hcl | 501 | 20 |
| Montelukast Sodium | Montelukast Sodium | 472 | 37 |
| Allopurinol | Allopurinol | 408 | 28 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 405 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 388 | 18 |
| Tramadol Hcl | Tramadol Hcl | 354 | 78 |
| Alendronate Sodium | Alendronate Sodium | 348 | 28 |
| Jardiance | Empagliflozin | 343 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 336 | 48 |
| Metformin Hcl Er | Metformin Hcl | 312 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 307 | 15 |
| Nifedipine Er | Nifedipine | 282 | 23 |
| Rivastigmine | Rivastigmine | 277 | 23 |
| Lamotrigine | Lamotrigine | 257 | 11 |
| Spironolactone | Spironolactone | 248 | 21 |
| Prednisone | Prednisone | 219 | 37 |
| Tizanidine Hcl | Tizanidine Hcl | 218 | 14 |
| Finasteride | Finasteride | 217 | 13 |
| Clonidine Hcl | Clonidine Hcl | 210 | 15 |
| Midodrine Hcl | Midodrine Hcl | 210 | 32 |
| Entresto | Sacubitril/Valsartan | 209 | 11 |
| Torsemide | Torsemide | 202 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 185 | 37 |
| Myrbetriq | Mirabegron | 185 | suppressed |
| Latanoprost | Latanoprost | 175 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 174 | 45 |
| Atenolol | Atenolol | 168 | 12 |
| Olanzapine | Olanzapine | 163 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 158 | 56 |
| Memantine Hcl Er | Memantine Hcl | 158 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 155 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 152 | 15 |
| Ezetimibe | Ezetimibe | 149 | 25 |
| Januvia | Sitagliptin Phosphate | 147 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 145 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 143 | suppressed |
| Lorazepam | Lorazepam | 142 | 29 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 140 | 12 |
| Pregabalin | Pregabalin | 139 | 16 |
| Warfarin Sodium | Warfarin Sodium | 139 | suppressed |
| Clonazepam | Clonazepam | 136 | 27 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 135 | 12 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 135 | 54 |
| Aripiprazole | Aripiprazole | 126 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 126 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 123 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 118 | 54 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 118 | suppressed |
| Digoxin | Digoxin | 116 | suppressed |
| Meloxicam | Meloxicam | 112 | 23 |
| Alprazolam | Alprazolam | 111 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 109 | 57 |
| Humalog Kwikpen U-100 | Insulin Lispro | 107 | 16 |
| Fenofibrate | Fenofibrate | 106 | suppressed |
| Xarelto | Rivaroxaban | 106 | suppressed |
| Calcitriol | Calcitriol | 105 | suppressed |
| Glipizide | Glipizide | 105 | 19 |
| Amantadine | Amantadine Hcl | 104 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 104 | suppressed |
| Lansoprazole | Lansoprazole | 102 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 100 | suppressed |
| Risperidone | Risperidone | 100 | suppressed |
| Ursodiol | Ursodiol | 100 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 98 | 12 |
| Rivastigmine | Rivastigmine Tartrate | 98 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 95 | suppressed |
| Primidone | Primidone | 95 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 94 | 18 |
| Lidocaine | Lidocaine | 92 | suppressed |
| Methocarbamol | Methocarbamol | 92 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 91 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 91 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 90 | 15 |
| Brilinta | Ticagrelor | 89 | suppressed |
| Hydrocortisone | Hydrocortisone | 88 | 13 |
| Enulose | Lactulose | 85 | suppressed |
| Chlorthalidone | Chlorthalidone | 84 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 84 | 17 |
| Ozempic | Semaglutide | 81 | 28 |
| Indapamide | Indapamide | 79 | suppressed |
| Ibuprofen | Ibuprofen | 78 | 23 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 76 | suppressed |
| Entacapone | Entacapone | 76 | suppressed |
| Bumetanide | Bumetanide | 75 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 75 | suppressed |
| Mounjaro | Tirzepatide | 75 | 21 |
| Nortriptyline Hcl | Nortriptyline Hcl | 75 | suppressed |
| Trulicity | Dulaglutide | 75 | 11 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 72 | 72 |
| Simvastatin | Simvastatin | 72 | 22 |
| Azithromycin | Azithromycin | 70 | 56 |
| Gemtesa | Vibegron | 70 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 69 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 68 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 66 | 22 |
| Farxiga | Dapagliflozin Propanediol | 65 | 13 |
| Novolog Flexpen | Insulin Aspart | 65 | 14 |
| Ceftriaxone | Ceftriaxone Sodium | 64 | 40 |
| Valsartan | Valsartan | 63 | 11 |
| Glipizide Er | Glipizide | 62 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 62 | 12 |
| Propranolol Hcl Er | Propranolol Hcl | 62 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 59 | 34 |
| Benztropine Mesylate | Benztropine Mesylate | 58 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 57 | suppressed |
| Linzess | Linaclotide | 57 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 57 | 28 |
| Glucagon Emergency Kit | Glucagon | 56 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 56 | 38 |
| Methenamine Hippurate | Methenamine Hippurate | 55 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 53 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 53 | 17 |
| Bupropion Hcl Sr | Bupropion Hcl | 52 | suppressed |
| Fluconazole | Fluconazole | 52 | 30 |
| Potassium Citrate Er | Potassium Citrate | 52 | suppressed |
| Tradjenta | Linagliptin | 52 | suppressed |
| Nadolol | Nadolol | 51 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 50 | suppressed |
| Colchicine | Colchicine | 49 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 49 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 48 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 46 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 46 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 46 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 45 | suppressed |
| Telmisartan | Telmisartan | 44 | 24 |
| Colesevelam Hcl | Colesevelam Hcl | 43 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 43 | 27 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 42 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 41 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 41 | 31 |
| Estradiol | Estradiol | 41 | 20 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 41 | suppressed |
| Celecoxib | Celecoxib | 40 | suppressed |
| Dextrose 5%-0.45% Nacl | Dextrose 5 %-0.45 % Sod Chlord | 40 | 11 |
| Cyclosporine | Cyclosporine | 39 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 39 | suppressed |
| Nystatin | Nystatin | 39 | 28 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 39 | suppressed |
| Acetylcysteine | Acetylcysteine | 38 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 38 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 38 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 38 | 11 |
| Phenytoin | Phenytoin | 38 | suppressed |
| Valproic Acid | Valproic Acid | 38 | suppressed |
| Lacosamide | Lacosamide | 37 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 37 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | 12 |
| Diazepam | Diazepam | 35 | suppressed |
| Levofloxacin | Levofloxacin | 35 | 22 |
| Oxycodone Hcl | Oxycodone Hcl | 35 | 11 |
| Rexulti | Brexpiprazole | 35 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 34 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 34 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 33 | 13 |
| Neupro | Rotigotine | 33 | suppressed |
| Ranolazine Er | Ranolazine | 33 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 32 | suppressed |
| Carbamazepine | Carbamazepine | 32 | suppressed |
| Lovastatin | Lovastatin | 32 | suppressed |
| Ketoconazole | Ketoconazole | 31 | 15 |
| Sodium Chloride | 0.9 % Sodium Chloride | 31 | 21 |
| Timolol Maleate | Timolol Maleate | 31 | suppressed |
| Topiramate | Topiramate | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 25 |
| Carbamazepine Er | Carbamazepine | 30 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 30 | 15 |
| Nystop | Nystatin | 30 | 25 |
| Amoxicillin | Amoxicillin | 29 | 15 |
| Cephalexin | Cephalexin | 29 | 21 |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 28 | suppressed |
| Ondansetron Odt | Ondansetron | 28 | 19 |
| Promethazine Hcl | Promethazine Hcl | 28 | 13 |
| Cilostazol | Cilostazol | 27 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 26 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 26 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 25 | suppressed |
| Haloperidol | Haloperidol | 24 | suppressed |
| Sotalol | Sotalol Hcl | 24 | suppressed |
| Dutasteride | Dutasteride | 23 | suppressed |
| Procrit | Epoetin Alfa | 23 | suppressed |
| Letrozole | Letrozole | 22 | suppressed |
| Mesalamine | Mesalamine | 22 | suppressed |
| Tegretol Xr | Carbamazepine | 22 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 22 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 21 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 21 | suppressed |
| Azathioprine | Azathioprine | 20 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 20 | suppressed |
| Erythromycin | Erythromycin Base | 20 | 15 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 15 |
| Scopolamine | Scopolamine | 19 | suppressed |
| Silodosin | Silodosin | 19 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 19 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 18 | 12 |
| Bicalutamide | Bicalutamide | 18 | suppressed |
| Budesonide | Budesonide | 18 | suppressed |
| Methadone Hcl | Methadone Hcl | 18 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 18 | suppressed |
| Vraylar | Cariprazine Hcl | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Clonidine | Clonidine | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 15 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 15 | suppressed |
| Movantik | Naloxegol Oxalate | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | 13 |
| Prezcobix | Darunavir/Cobicistat | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Ethosuximide | Ethosuximide | 14 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 13 | suppressed |
| Calcium Acetate | Calcium Acetate | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Matzim La | Diltiazem Hcl | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 13 | suppressed |
| Zonisamide | Zonisamide | 13 | suppressed |
| Ceftazidime | Ceftazidime | 12 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Risperidone Odt | Risperidone | 12 | suppressed |
| Sodium Chloride | Sodium Chloride 0.45 % | 12 | 11 |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 11 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 11 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 11 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 11 | suppressed |
| Progesterone | Progesterone, Micronized | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $488.88 · 24 records | PFIZER INC. | BREZTRI, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, KISUNLA, NURTEC ODT, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, The Cologuard Plus Collection Kit, VYNDAMAX, XIFAXAN, ZAVZPRET | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error